Pancreatic Cancer Research

ResearcherTianjin Medical University Cancer Institute and HospitalActive in the last 2 years

Huizhi Sun

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0009-0007-7375-7994; OpenAlex author ID A5101114501. Sources: OpenAlex.

Their work

Papers
12 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
24
Papers, trials and grants by year

2021: 3 papers · 2022: 3 papers · 2023: 1 paper · 2024: 3 papers · 2025: none · 2026: 2 papers

Papers 12

  1. Tumor-Derived Interleukin 35 Promotes Fibrosis in the Tumor Microenvironment of Pancreatic Cancer by Activating Pancreatic Stellate Cells. First author DOI 10.1002/advs.202509074↗
  2. Retraction Note: BICC1 drives pancreatic cancer progression by inducing VEGF-independent angiogenesis. Co-author DOI 10.1038/s41392-025-02561-9↗
  3. Tumor-derived interleukin 35 mediates the dissemination of gemcitabine resistance in pancreatic adenocarcinoma. Co-author DOI 10.1038/s41388-024-02938-0↗
  4. Correction: BICC1 drives pancreatic cancer progression by inducing VEGF-independent angiogenesis. Co-author DOI 10.1038/s41392-023-01721-z↗
  5. BICC1 drives pancreatic cancer stemness and chemoresistance by facilitating tryptophan metabolism. Co-author DOI 10.1126/sciadv.adj8650↗
  6. BICC1 drives pancreatic cancer progression by inducing VEGF-independent angiogenesis. Co-author DOI 10.1038/s41392-023-01478-5↗
  7. Genome-wide CRISPR screen identifies MTA3 as an inducer of gemcitabine resistance in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.canlet.2022.215864↗
  8. ENO1 expression and Erk phosphorylation in PDAC and their effects on tumor cell apoptosis in a hypoxic microenvironment. Co-author DOI 10.20892/j.issn.2095-3941.2022.0451↗
  9. MIF promotes cell invasion by the LRP1-uPAR interaction in pancreatic cancer cells. Co-author DOI 10.3389/fonc.2022.1028070↗
  10. PERK-eIF2α-ERK1/2 axis drives mesenchymal-endothelial transition of cancer-associated fibroblasts in pancreatic cancer. Co-author DOI 10.1016/j.canlet.2021.05.021↗
  11. Hypoxic microenvironment induced spatial transcriptome changes in pancreatic cancer. Co-author DOI 10.20892/j.issn.2095-3941.2021.0158↗
  12. OXCT1 Enhances Gemcitabine Resistance Through NF-κB Pathway in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3389/fonc.2021.698302↗

Closest collaborators

The 24 strongest of 24 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Chongbiao Huang · 10 shared papers, 2021–2026 · strength 1.67
  2. Jihui Hao · 10 shared papers, 2021–2026 · strength 1.65
  3. Xiuchao Wang · 7 shared papers, 2021–2026 · strength 1.15
  4. Tiansuo Zhao · 7 shared papers, 2021–2026 · strength 1.15
  5. Chao Xu · 5 shared papers, 2023–2026 · strength 0.98
  6. Song Gao · 6 shared papers, 2021–2024 · strength 0.91
  7. Jing Liu · 6 shared papers, 2021–2024 · strength 0.91
  8. Zengxun Li · 4 shared papers, 2023–2026 · strength 0.74
  9. Shengyu Yang · 4 shared papers, 2023–2024 · strength 0.66
  10. Hui Li · 3 shared papers, 2024–2026 · strength 0.66
  11. Peng Xie · 2 shared papers, 2024–2026 · strength 0.42
  12. Yukuan Feng · 2 shared papers, 2024–2026 · strength 0.42
  13. Run-Fen Cheng · 3 shared papers, 2021–2022 · strength 0.41
  14. Wei Lin · 1 shared paper, 2026 · strength 0.25
  15. Chuntao Gao · 2 shared papers, 2021 · strength 0.23
  16. Danqi Fu · 1 shared paper, 2024 · strength 0.17
  17. Liangliang Wu · 1 shared paper, 2022 · strength 0.13
  18. Yizhang Zhou · 1 shared paper, 2021 · strength 0.12
  19. Yang Liu · 1 shared paper, 2021 · strength 0.12
  20. Jinsheng Ding · 1 shared paper, 2021 · strength 0.12
  21. Yongjie Xie · 1 shared paper, 2021 · strength 0.12
  22. Xugang Sun · 1 shared paper, 2021 · strength 0.11
  23. Fanjie Jin · 1 shared paper, 2021 · strength 0.11
  24. Wenrun Cai · 1 shared paper, 2021 · strength 0.11

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.